Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Psoriasis

Psoriasis

Subtypes of Psoriasis

Plaque psoriasis 12 Erythrodermic psoriasis 1 Generalized pustular psoriasis 1 Inverse Psoriasis 1

33 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Psoriasis

289 trials tracked for Psoriasis: 148 in phase 3 or 4 and 52 with published results. The most-cited published study has 835 citations.

289Trials tracked
148Phase 3 & 4
0Recruiting
52With published results
Phase distribution
Phase 4 50 Phase 3 98 Phase 2 85 Phase 1 21 Other / NA 35
  1. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis Completed · 835 cited
  2. Phase 4 Mechanism of Action Study for Psoriasis Completed · 721 cited
  3. Phase 3 Etanercept (Enbrel®) in Psoriasis - Pediatrics Completed · 388 cited
  4. Phase 3 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis Completed · 372 cited
  5. Phase 3 BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 295 cited
  6. Phase 3 BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment Completed · 213 cited
Show 44 more trials
  1. Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 154 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 154 cited
  3. Phase 4 Vascular Inflammation in Psoriasis - Extension Study Completed · 146 cited
  4. Phase 4 Vascular Inflammation in Psoriasis Trial (The VIP Trial) Completed · 146 cited
  5. Phase 3 A Study in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 132 cited
  6. Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 130 cited
  7. Phase 3 Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis Completed · 87 cited
  8. Phase 3 A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis Completed · 86 cited
  9. Phase 3 Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis Completed · 82 cited
  10. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Completed · 81 cited
  11. Phase 3 A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis Completed · 79 cited
  12. Phase 3 A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis Completed · 71 cited
  13. Phase 3 A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Completed · 68 cited
  14. Phase 3 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 55 cited
  15. Phase 3 A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis Completed · 54 cited
  16. Phase 3 A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Completed · 54 cited
  17. Phase 3 Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy Completed · 54 cited
  18. Phase 3 BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 53 cited
  19. Phase 3 BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 53 cited
  20. Phase 3 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Completed · 49 cited
  21. Phase 3 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp Completed · 47 cited
  22. Phase 4 Vascular Inflammation in Psoriasis - Apremilast Completed · 44 cited
  23. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 38 cited
  24. Phase 3 Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis Completed · 38 cited
  25. Phase 3 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis Completed · 33 cited
  26. Phase 3 A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Completed · 28 cited
  27. Phase 3 The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis Completed · 27 cited
  28. Phase 3 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis Completed · 26 cited
  29. Phase 3 An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis Completed · 25 cited
  30. Phase 3 Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis Completed · 25 cited
  31. Phase 4 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy Completed · 21 cited
  32. Phase 3 A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Completed · 20 cited
  33. Phase 3 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age Completed · 17 cited
  34. Phase 3 Study of Secukinumab With 2 mL Pre-filled Syringes Completed · 17 cited
  35. Phase 3 A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis Completed · 15 cited
  36. Phase 4 A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies Completed · 14 cited
  37. Phase 3 A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Completed · 13 cited
  38. Phase 3 A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 11 cited
  39. Phase 4 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed · 10 cited
  40. Phase 3 Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed · 8 cited
  41. Phase 3 A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Completed · 4 cited
  42. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 in Japanese Participants With Moderate-to-Severe Psoriasis Completed · 3 cited
  43. Phase 3 An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea Completed · 3 cited
  44. Phase 4 A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life Completed · 2 cited

Showing the 50 most-cited and recently-updated of 289 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Rheumatology Cohort
Secukinumab improves skin response in Chinese patients with psoriatic arthritis Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
Frontiers Apr 23, 2026
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis
OB/GYN & Women's Health Cohort
Autoimmune Thyroiditis Prevalence Higher in Obese Women With PCOS in Retrospective Cohort Analysis New PCOS Data Reveals Hidden Thyroid Risks
This retrospective cohort study evaluated 1,249 women with PCOS aged 18–44 years.
Women with PCOS should check their thyroid health regularly.
Frontiers Apr 22, 2026
MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study
Dermatology Cohort
MONO, ORM1, ORM2, and AGP levels show excellent diagnostic value for psoriasis identification in a retrospective case-control study New Blood Test Could Spot Psoriasis Earlier, Study Suggests
This retrospective case-control study evaluated MONO, ORM1, ORM2, and AGP levels in 140 participants, including 70 patients with dermatology…
This research offers a new way to spot psoriasis risk early using a simple blood test, which could lead to faster treatment and better skin …
Frontiers Apr 22, 2026
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older
Dermatology FDA Approval
FDA Approves Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older The FDA has approved a new drug called Cosentyx for treating a serious skin condition
The FDA approved Cosentyx (secukinumab) for moderate to severe plaque psoriasis in adults and pediatric patients 6 years and older who are c…
The FDA approved Cosentyx for moderate to severe plaque psoriasis in adults and children 6 and older.
FDA Apr 22, 2026
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome
Diabetes & Endocrinology Sys. Review
Case report describes secukinumab use in a woman with erythrodermic psoriasis and systemic capillary leak syndrome One case report links secukinumab to severe capillary leak syndrome in a woman with psoriasis
This case report details the clinical course of a 66-year-old woman with new-onset erythrodermic psoriasis who developed systemic capillary …
A woman with psoriasis developed life-threatening capillary leak syndrome after starting secukinumab, with symptoms improving only after sto…
Frontiers Apr 21, 2026
Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk
Dermatology
Review of cohort data finds AD linked to psoriasis risk and biologics associated with lower risk Atopic Dermatitis Raises Psoriasis Risk, But Biologics Help
This narrative review synthesizes findings from a large cohort study.
A massive study shows that while eczema increases the chance of getting psoriasis, modern biologic drugs significantly protect against this …
medRxiv Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA approved a drug called Stelara to treat several inflammatory conditions in adults and children
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
FDA approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults an…
FDA Apr 21, 2026
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Dermatology FDA Approval
FDA Approves Stelara (ustekinumab) for moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis The FDA has approved a new drug called Stelara for several inflammatory conditions
The FDA approved ustekinumab for adult and pediatric patients 6 years and older with moderate to severe plaque psoriasis and active psoriati…
The FDA has approved Stelara to treat moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in a…
FDA Apr 21, 2026
IL-17A inhibition improves skin lesions and early atherosclerosis markers in psoriasis vulgaris patients
Cardiology Cohort
IL-17A inhibition improves skin lesions and early atherosclerosis markers in psoriasis vulgaris patients Psoriasis Is Linked to Heart Disease — and One Drug May Help Both
This retrospective cohort and prospective intervention study evaluated IL-17A inhibitors for psoriasis vulgaris and associated cardiovascula…
Psoriasis and heart disease share deep biological roots, and a specific drug may improve both conditions at once.
Frontiers Apr 18, 2026
Higher composite dietary antioxidant index associated with lower all-cause mortality in psoriasis patients
Nutrition & Obesity Medicine Cohort
Higher composite dietary antioxidant index associated with lower all-cause mortality in psoriasis patients Higher dietary antioxidants linked to lower death risk in psoriasis patients
This prospective cohort study evaluated 500 individuals with psoriasis from the NHANES database.
Psoriasis patients who eat more antioxidants face a lower risk of death, according to a study tracking 500 people over more than a decade.
Frontiers Apr 14, 2026
CXCL13 quantification in PBMCs and plasma distinguishes Sézary syndrome from other cutaneous T-cell lymphomas and dermatoses
Allergy & Immunology Cohort
CXCL13 quantification in PBMCs and plasma distinguishes Sézary syndrome from other cutaneous T-cell lymphomas and dermatoses A simple blood test could spot a rare skin cancer faster
This cohort study analyzed CXCL13 expression in peripheral blood mononuclear cells (PBMCs) and plasma concentrations in patients with suspec…
A simple blood test for a protein called CXCL13 may help doctors catch a rare, aggressive skin cancer that often looks like eczema for years…
Frontiers Apr 13, 2026
Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients
Diabetes & Endocrinology RCT
Secukinumab improves cutaneous adipose tissue inflammatory signatures in psoriasis patients Fat Under Your Skin Fuels Psoriasis Inflammation
This randomized placebo-controlled trial evaluated secukinumab in 82 patients with psoriasis.
Your body fat is not just storing energy; it is actively making your psoriasis worse, and new treatments are finally targeting this hidden f…
Apr 10, 2026

Questions about Psoriasis

Are there regional differences in health issues for people with psoriasis?

Yes, regional differences exist in psoriasis-related health issues, including comorbidities, treatment patterns, and healthcare access, as shown by studies from North America, Europe, Asia, and Africa.

Full answer →
Is secukinumab effective for Chinese patients with psoriatic arthritis?

Yes, secukinumab is effective for Chinese patients with psoriatic arthritis, with real-world data and cost-effectiveness analyses supporting its use.

Full answer →